中文名稱  磷酸化成視網(wǎng)膜細(xì)胞瘤蛋白抗體規(guī)格 

英文名稱  Anti-phospho-Rb/p105-Rb(Ser780)

別    名 Rb(Phospho-Ser780); OSRC; P105 RB; P105RB; PP105; PP110; pRb; RB 1; RB1; RB1 protein; Retinoblastoma 1 (including osteosarcoma); Retinoblastoma 1; Retinoblastoma associated protein; Including osteosarcoma; Osteosarcoma; p105-Rb; Rb; RB_HUMAN; Retinoblastoma suspectibility protein; Retinoblastoma-associated protein; Retinoblastoma related osteosarcoma; Retinoblastoma susceptibility gene.

產(chǎn)品屬性：

磷酸化成視網(wǎng)膜細(xì)胞瘤蛋白抗體規(guī)格 濃    度  1mg/1ml

規(guī) 格  0.1ml/100μg

抗體來(lái)源  Rabbit

克隆類(lèi)型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Chicken, Dog, Cow

產(chǎn)品類(lèi)型   一抗 磷酸化抗體  

研究領(lǐng)域     細(xì)胞生物 免疫學(xué) 染色質(zhì)和核信號(hào) 表觀遺傳學(xué)

蛋白分子量  predicted molecular weight: 106kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated Synthesised phosphopeptide derived from human Rb around the phosphorylation site of (Ser780)

亞    型  IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化成視網(wǎng)膜細(xì)胞瘤蛋白抗體規(guī)格 產(chǎn)品應(yīng)用   WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 Nuclear Marker.

The protein encoded by this gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma.

Function : Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. ecruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the epressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity.

Subunit : Interacts with ATAD5. Interacts with PRMT2, CDK1 and CDK2. The hypophosphorylated form interacts with and sequesters the E2F1 transcription factor. Interacts with heterodimeric E2F/DP transcription factor complexes containing TFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. The unphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1, MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain of TAF1. Interacts with AATF, DNMT1, LIN9, LMNA, SUV420H1, SUV420H2, PELP1 and TMPO-alpha. May interact with NDC80. Interacts with GRIP1 and UBR4. Interacts with ARID4A and KDM5B. Interacts with E4F1 and LIMD1. Interacts with SMARCA4/BRG1 AND HDAC1. Interacts with adenovirus E1A protein, HPV E7 protein and SV40 large T antigen. Interacts with PSMA3 and USP4. Interacts (when methylated at Lys-860) with L3MBTL1.

Subcellular Location : Nucleus.

Tissue Specificity : Expressed in the retina.

Post-translational modifications : Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 at Ser-567 in G1, thereby releasing E2F1 which is then able to activate cell growth. Dephosphorylated at the late M phase. SV40 large T antigen, HPV E7 and adenovirus E1A bind to the underphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domain C and the Pocket domain, and thereby inhibits interactions with heterodimeric E2F/DP transcription factor complexes. Dephosphorylated at Ser-795 by calcineruin upon calcium stimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 and Ser-811 is required for G0-G1 transition. Phosphorylated by CDK1 and CDK2 upon TGFB1-mediated apoptosis.

N-terminus is methylated by METTL11A/NTM1. Monomethylated at Lys-860 by SMYD2, promoting interaction with L3MBTL1.

DISEASE : Defects in RB1 are the cause of childhood cancer retinoblastoma (RB) [MIM:180200]. RB is a congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20'000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases. Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil ('cat eye') is investigated.

Defects in RB1 are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Defects in RB1 are a cause of osteogenic sarcoma (OSRC) [MIM:259500].

Similarity : Belongs to the retinoblastoma protein (RB) family.

Database links : UniProtKB/Swiss-Prot: P06400.2

核標(biāo)志物

實(shí)驗(yàn)流程：

全、新、優(yōu)、品、好四大特點(diǎn)：

磷酸化成視網(wǎng)膜細(xì)胞瘤蛋白抗體規(guī)格 全：公司提供上萬(wàn)種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細(xì)胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團(tuán)隊(duì)，產(chǎn)品一旦售出，實(shí)驗(yàn)過(guò)程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時(shí)沒(méi)有任何的后顧之憂。

技術(shù)外包服務(wù):

★磷酸化成視網(wǎng)膜細(xì)胞瘤蛋白抗體規(guī)格 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測(cè)序、載體構(gòu)建等

★蛋白工程：原核、哺乳動(dòng)物蛋白表達(dá)系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細(xì)胞工程：細(xì)胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細(xì)胞培養(yǎng)、細(xì)胞膜制備、穩(wěn)定細(xì)胞株構(gòu)建、細(xì)胞RNAi技術(shù)等等。

正在熱銷(xiāo)的相關(guān)產(chǎn)品：

HSP-90 Alpha(Heat Shock Protein 90 Alpha ) 熱休克蛋白90α抗體Multi-class antibodies規(guī)格： 0.5mg

Anti-phospho-c-Abl(Tyr204) 磷酸化非受體酪氨酸激酶c-Abl抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh phospho-CHEK1 (Ser280) 磷酸化細(xì)胞周期檢測(cè)點(diǎn)激酶1抗體 規(guī)格 0.1ml

兔抗豬IgG血清 0.5ml 國(guó)產(chǎn)

Wnt11 英文名稱： 信號(hào)通路Wnt11抗體 0.1ml

Phospho-Doublecortin (Ser128) 英文名稱： 磷酸化雙皮質(zhì)素抗體 0.1ml

Anti-phospho-c-Abl(Tyr204) 磷酸化非受體酪氨酸激酶c-Abl抗體Multi-class antibodies規(guī)格： 0.1ml

Anti-Plectin/FITC 熒光素標(biāo)記網(wǎng)蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rat IgG (親和純化) 大鼠IgGMulti-class antibodies規(guī)格： 1mg

高遷移率族蛋白-1抗體 Anti-HMGB1 0.1ml

Goat Anti-Guinea pig IgG 羊抗豚鼠IgG 1mg

FGF8 英文名稱： 成纖維細(xì)胞生長(zhǎng)因子8抗體 0.1ml

Rhesus antibody Rh Phospho-RelB(Ser573) 磷酸化核轉(zhuǎn)錄因子NFKB-RelB蛋白抗體 規(guī)格 0.1ml

Rat IgG (親和純化) 大鼠IgGMulti-class antibodies規(guī)格： 1mg

synaptotagmin-2 英文名稱： 突觸結(jié)合蛋白相關(guān)基因2抗體 0.1ml

phospho-MEK1 + MEK2 (Ser222 + Ser226) 英文名稱： 磷酸化原活化蛋白激酶1抗體 0.1ml

CD3抗體 Anti-CD3 0.1ml

Anti-VDCC-L Beta/FITC 熒光素標(biāo)記L-型電壓依賴型鈣通道β抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Phospho-GSK3 alpha(Ser21) 磷酸化葡萄糖合成激酶3α抗體 GSK3α(Phospho-Ser21) 規(guī)格 0.1ml

CD62L (ELAM-1/L-Selectin ) L選擇素抗原Multi-class antibodies規(guī)格： 0.5mg

人臍平滑肌細(xì)胞

NCI-H358 人非小細(xì)胞細(xì)胞

FCER2 Others Mouse 小鼠 FCER2A / CD23 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

LX-2, 人肝星形細(xì)胞株

人胚;IMR-90

人臍內(nèi)皮細(xì)胞;HUV-EC-C 人甲狀腺濾泡上皮細(xì)胞完全培養(yǎng)基 100mL

CL-0224SW579(人甲狀腺鱗癌細(xì)胞 )5×106cells/瓶×2

PARP1 Others Human 人 PARP-1 / PARP 桿狀病毒-昆蟲(chóng)細(xì)胞裂解液 (陽(yáng)性對(duì)照)

人淋巴成纖維細(xì)胞cDNAHLF cDNA

F9細(xì)胞， 人肺泡上皮細(xì)胞,HPAEpiC細(xì)胞 肝實(shí)質(zhì)細(xì)胞Many types of cells包裝：5 ×105次方(1ml)

狗腎細(xì)胞;Super Tube

THPO Others Mouse 小鼠 Thrombopoietin / THPO / TPO 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

磷酸化成視網(wǎng)膜細(xì)胞瘤蛋白抗體規(guī)格 人臍平滑肌細(xì)胞

NCI-H358 人非小細(xì)胞細(xì)胞

FCER2 Others Mouse 小鼠 FCER2A / CD23 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

LX-2, 人肝星形細(xì)胞株

人胚;IMR-90

人臍內(nèi)皮細(xì)胞;HUV-EC-C 人甲狀腺濾泡上皮細(xì)胞完全培養(yǎng)基 100mL